RVU330

RVU330 is an investigational **small-molecule** dual adenosine receptor antagonist developed by **Ryvu Therapeutics** for oncology. It is designed to block both the **adenosine A2A receptor** and **adenosine A2B receptor**, thereby counteracting adenosine-driven immunosuppression within the tumor microenvironment. Preclinical reports describe sub- or low-nanomolar antagonistic potency at both receptors, including under high-adenosine conditions typical of solid tumors, with restoration of immune-cell activity in CD4-positive T cells, CD8-positive T cells, and monocyte-derived dendritic cells. The program was reported in **preclinical development** for cancer, with antitumor activity shown in syngeneic mouse models.